More suggestive
Reduced sexual desire, fewer spontaneous or morning erections, loss of body hair, testicular changes, hot flushes and unexplained low bone density can strengthen clinical suspicion.
TESTOSTERONE / A CLINICAL GUIDE
Low testosterone, conflicting advice or symptoms that are difficult to explain? The important question is not simply how to raise a number. It is what that number means for you.
A considered guide to testing, diagnosis, treatment decisions, fertility, contraindications and monitoring.
A RESULT IS NOT A DIAGNOSIS
A man with a testosterone level of 11 nmol/L might have genuine hormone deficiency, a temporary reduction from illness, an obesity-related change in binding proteins, or no meaningful androgen deficiency at all. His symptoms may also have another cause.
Clinical assessment asks three separate questions: Are the symptoms compatible with deficiency? Are hormone levels consistently low? And what is causing the change? Treatment only makes sense once those questions have been considered.
INTERACTIVE / THREE EXAMPLES
Explore three simplified patterns. These examples illustrate clinical reasoning; they do not diagnose an individual result.
PATTERN 01 / TESTICULAR SIGNAL
Low testosterone with elevated LH may suggest primary testicular dysfunction. A physician considers symptoms, repeats the blood test and investigates the cause.
A treatment discussion may be appropriate after diagnosis, but fertility intentions and safety still matter.
Illustrative patterns only. Values, reference ranges and assay methods differ; SHBG and calculated free testosterone require careful interpretation.
02 / CLINICAL PRESENTATION
Some symptoms are more suggestive of androgen deficiency than others. None is sufficient on its own.
Reduced sexual desire, fewer spontaneous or morning erections, loss of body hair, testicular changes, hot flushes and unexplained low bone density can strengthen clinical suspicion.
Fatigue, poor concentration, depressed mood, reduced exercise performance, changes in body composition and erectile difficulties also occur with sleep disorders, medication effects, mental illness and cardiometabolic disease.
Erectile dysfunction is not synonymous with testosterone deficiency. Vascular, medication-related, neurological, psychological and relationship factors may contribute.
03 / THE WORKUP
The diagnosis requires symptoms or signs that fit and consistently low hormone measurements, not one isolated result.
Measure total testosterone early in the morning, ideally fasting and when not acutely unwell.
Repeat a low result on another morning. Testosterone varies across days and with illness, food and sleep.
LH and FSH help distinguish testicular failure from hypothalamic–pituitary causes.
SHBG and calculated free testosterone can be informative when total testosterone is borderline or binding proteins are altered.
Not every patient needs every test. The workup is guided by the clinical history and examination.
A single universal testosterone threshold does not settle every case. Interpretation depends on symptoms, assay, repeat measurements, SHBG and the underlying cause. Australian PBS subsidy criteria are separate from the clinical decision to diagnose or treat.
BEYOND TOTAL TESTOSTERONE / THE BIOMARKER MAP
A sophisticated hormone report can contain twenty numbers. The useful question is what each one changes about a clinical decision.
Explore a marker to understand what it measures, when it may be useful, and what it cannot tell you. This is a guide to interpretation, not a recommendation to order every test.
Read Dr Wee's hormone-lab guide ↗FOUNDATION & DIAGNOSIS
CAUSE & SYSTEMIC CONTEXT
ADDED BY JUDGEMENT
The starting measurement, but not a stand-alone diagnosis.
Two properly timed, separate morning measurements help establish whether a low concentration is persistent.
A single low result does not identify the cause or mean testosterone treatment is necessary.
Why the categories matter. Total testosterone, LH/FSH and relevant SHBG assessment help answer a different question from cortisol, IGF-1 or DHT. An extended panel is justified when it has a clear clinical purpose, not simply because it is available.
04 / THE CAUSE
Testosterone is regulated through the hypothalamus, pituitary gland and testes. Finding the site of the problem changes the next decision.
Testosterone is low despite an elevated LH signal. Causes include testicular injury, genetic conditions, chemotherapy or other testicular disease.
Testosterone is low with low or inappropriately normal LH. Medication effects, pituitary disorders and other central causes require assessment.
Obesity, significant illness, sleep disruption and some medications can lower testosterone without irreversible testicular failure. The underlying condition may be the first treatment target.
05 / BEFORE CONSIDERING TREATMENT
A low result should prompt curiosity about what else is happening in the body, not an automatic prescription.
Sleep apnoea, obesity, chronic illness, medications, excessive alcohol, low energy availability, depression and iron disorders can all complicate the picture. Some are causes of reduced testosterone; others produce similar symptoms.
Correcting a genuine nutritional deficiency is sensible. Supplementing zinc, magnesium or vitamin D when levels are adequate has not been established as a reliable treatment for hypogonadism.
06 / TREATMENT DECISIONS
For men with confirmed symptomatic hypogonadism, treatment can be appropriate after discussing likely benefits, limitations, alternatives and monitoring obligations.
Symptoms, repeat biochemical results, LH/FSH, relevant examination and investigation of the cause inform the decision.
For some men, treatment of a reversible cause is preferable. For others, hormone replacement is appropriate. Treatment may be delivered by daily topical preparations or longer-interval injections. Practical differences matter, and not every route suits every patient.
Fertility, prostate assessment, blood count, cardiovascular history, sleep disorders, treatment burden and follow-up all matter before commencement.
A DECISION PATHWAY / BEFORE SELECTING A FORMULATION
TREATMENT / ROUTES OF DELIVERY
The method affects daily routine, dose adjustment, blood-test timing, potential transfer to others and how quickly treatment can be stopped. No route is automatically right for everyone.
HOW IT FITS INTO LIFE
Transdermal gel is absorbed through the skin. The amount absorbed differs between individuals, so monitoring and dose adjustment are important.
POTENTIAL ADVANTAGES
Daily dosing offers a relatively flexible way to adjust or stop treatment when necessary, without an injection.
PRACTICAL LIMITATIONS
Daily adherence matters. Skin reactions, timing of washing and accidental transfer to partners or children require attention.
AN IMPORTANT CONSIDERATION
The application site and timing of blood collection depend on the exact formulation. Follow the prescribed product instructions.
GRAPHIC / ADMINISTRATION RHYTHM
This shows how often treatment may be administered, not the testosterone level in the blood.
Intervals are illustrative, not prescribing instructions. Initial loading schedules, clinical response and formulation-specific product information can change timing. Shorter-acting injections may be administered on a different schedule.
OTHER ROUTES
Other testosterone delivery systems are described in international literature. They are not necessarily routinely available, registered or suitable for the same indications in Australia. Availability and evidence must be checked locally; this page focuses on the principal Australian topical and injectable routes.
AN ESSENTIAL CONVERSATION
External testosterone suppresses LH and FSH and can markedly reduce sperm production. Recovery after cessation may take months or longer and is not always predictable. Men who wish to conceive now or in the future should discuss fertility before any treatment. Specialist fertility-preserving approaches may be available in selected cases.
07 / CONTRAINDICATIONS & CAUTION
Some conditions mean testosterone should not be commenced. Others require investigation, stabilisation or specialist advice. Individual circumstances matter.
GENERALLY DO NOT COMMENCE / DEFER
REQUIRES INDIVIDUAL RISK REVIEW
This is a patient-facing overview, not a complete prescribing checklist. Contraindication classifications differ between professional guidelines. A physician should assess current guidance and individual circumstances.
08 / WHAT THE EVIDENCE SAYS
Large trials are valuable, but their conclusions apply to the patients, formulations and doses studied.
MAJOR ADVERSE CARDIOVASCULAR EVENTS
TRAVERSE: approximately 5,200 men with hypogonadism and established or elevated cardiovascular risk.
TRAVERSE found testosterone treatment was noninferior to placebo for its primary major cardiovascular endpoint in the population studied. Sexual outcomes and anaemia improved in some men, generally with modest average effects.
Atrial fibrillation, pulmonary embolism and acute kidney injury were reported more often in the testosterone group. A subsequent fracture analysis also found more clinical fractures. These signals deserve discussion rather than dismissal.
The study does not establish the safety or benefits of testosterone for otherwise healthy men seeking supraphysiological “optimisation.”
AN INTERACTIVE EVIDENCE LEDGER
Select an outcome category, or view all findings together. These are trial results, not predictions for an individual patient.
Corrected more often at 6 months: 41.0% vs 27.5%. Relevant to confirmed deficiency only.
Sexual activity +0.49 acts/day vs placebo at 6 months, sustained to 24 months. Erectile function: no difference (p = 0.44).
Small but significant gains across all 5,204 men, including the 2,643 (50.8%) with depressive symptoms.
Prediabetes to diabetes: 7.8% vs 10.7% at 12 months, 10.1% vs 14.6% at 24 months. Not statistically significant.
No significant difference from placebo in 5,204 men, including those with depressive symptoms.
High-grade cancer 0.19% vs 0.12% (5 vs 3 men); any prostate cancer 12 vs 11 men. Higher-risk men excluded.
3.50% vs 2.46% (154 vs 97 men; HR 1.43). The cause remains uncertain.
3.5% vs 2.4%. Relevant to arrhythmia history and cardiac comorbidity.
AKI 2.3% vs 1.5%; pulmonary embolism ~0.9% vs 0.5%. Small event counts.
Percentage of participants; the same 0–8% horizontal scale is used throughout.
These are separate trial outcomes, not additive risks. The fracture analysis used a slightly different analysis population and follow-up than the primary cardiovascular outcome. Differences do not automatically establish causation.
TRAVERSE enrolled symptomatic men aged 45–80 with repeated low morning testosterone and pre-existing or elevated cardiovascular risk. It tested titrated transdermal gel, not every formulation, not supraphysiological dosing, and not indefinite treatment in younger, otherwise healthy men. The primary conclusion concerned cardiovascular noninferiority, not cardiovascular benefit.
Dr Wee's detailed commentary ↗09 / LONGITUDINAL CARE
When treatment is commenced, follow-up is part of the treatment itself. The aim is symptom benefit with physiological levels and acceptable risk.
Diagnosis, symptom priorities, fertility, examination, haematocrit, prostate assessment where appropriate, comorbidities and shared decisions.
Review symptoms, adverse effects, adherence and testosterone level at formulation-appropriate timing; assess blood count and other indicated measures.
Periodic review of benefit, haematocrit, prostate risk, sleep, cardiovascular health and whether the original treatment goals remain relevant.
A haematocrit above 54% during treatment generally requires prompt reassessment and treatment adjustment or interruption. Exact monitoring intervals and blood-sampling timing differ between gel, cream and injectable preparations. Blood tests at the wrong time can be misleading.
SOURCES / FURTHER READING
This patient guide draws on Australian medicine information and the British Society for Sexual Medicine's 2023 guidance. Recommendations and available products differ across jurisdictions.
10 / COMMON QUESTIONS
Clear answers often begin with understanding what a result cannot tell us.
Usually not as a universal panel. Total testosterone measured on two appropriate mornings, LH/FSH and SHBG when indicated are more directly relevant to the diagnosis. Estradiol, DHT, cortisol and related tests become useful when symptoms, examination or other results suggest a specific problem.
No. The prespecified diabetes substudy did not find a significant reduction in diabetes progression or improved glycaemic control. A separate fracture analysis observed more clinical fractures in the testosterone arm; the reason is not fully understood.
Monitoring generally includes symptom response, serum testosterone at a formulation-appropriate time and full blood count/haematocrit. Prostate assessment, cardiometabolic factors and other tests are individualised according to age, risk, symptoms and treatment course.
Neither is automatically better. Gels or creams avoid injections and may be easier to adjust, but involve daily application and transfer precautions. Shorter-acting injections require more frequent administration and can produce fluctuating levels. Longer-acting injections reduce visit frequency but take longer to wear off if problems arise. The diagnosis, fertility plans, preferences and monitoring needs determine the choice.
Both deliver testosterone through the skin, but they are distinct formulations. Absorption, application sites, dose measurement and the timing of blood tests are product-specific. A cream designed for one site should not simply be used as a gel intended for another.
Oral and nasal testosterone formulations are described internationally, but access and suitability vary by country and product. A clinician needs to check Australian registration, evidence and individual circumstances rather than assuming overseas options are available locally.
It may be borderline depending on the laboratory and circumstances. Symptoms, repeat fasting morning measurements, SHBG, calculated free testosterone when indicated and LH/FSH are more informative than the number alone.
It can help some men with confirmed deficiency, particularly with reduced sexual desire, but erectile dysfunction commonly has vascular, medication-related or psychological contributors. A broader sexual and cardiovascular assessment may be needed.
Yes. External testosterone can suppress sperm production, sometimes profoundly. Discuss future fertility before treatment. Recovery after stopping is variable; specialist alternatives may be appropriate.
Current trial evidence has not demonstrated a clear increase in prostate cancer diagnoses over the periods studied in appropriately selected men. This does not establish lifetime safety or make treatment suitable for someone with known prostate cancer. Baseline risk assessment and monitoring remain important.
Yes. Obesity, significant illness, sleep disturbance and some medications can contribute to lower testosterone or similar symptoms. Investigating and treating these factors may change the treatment decision.
Some men with permanent testicular or pituitary disease need long-term replacement. Others may have reversible causes or decide to stop if benefit is limited. Stopping treatment can temporarily leave endogenous production suppressed, so discontinuation should be planned with a clinician.
No. Pituitary imaging is considered when symptoms, marked biochemical abnormalities or other findings raise concern for pituitary disease. It is not a routine investigation for every borderline result.
THE CURA CONTINUUM
A physician relationship is not defined by whether a medicine is prescribed. It is defined by careful decisions and what happens after them.
Begin with your concerns, priorities and circumstances.
Interpret symptoms, investigations and the underlying cause.
Weigh options, benefits, uncertainties and trade-offs.
Coordinate decisions and provide continuity when needed.
A FINAL THOUGHT
Some men have a genuine testosterone deficiency and benefit from replacement. Others have a low number for reasons that deserve a different response. The point of an assessment is to tell the difference.
Begin Conversation ↗Explore men's health ↗Read Dr Wee's longer guide ↗